MyFinsight
Home
Blog
About
Proceeds from the
exercise of stock options
$1,604K
Net cash provided by
financing activities
$1,604K
(-98.39%↓ Y/Y)
Net increase in cash
and cash...
-$28,313K
(-183.34%↓ Y/Y)
Canceled cashflow
$1,604K
Stock-based compensation
expense
$3,104K
(-40.54%↓ Y/Y)
Accretion of debt discount
and non-cash...
$1,291K
(11.39%↑ Y/Y)
Accounts payable
$1,011K
(206.09%↑ Y/Y)
Depreciation and
amortization
$523K
(-60.85%↓ Y/Y)
Non-cash lease expense
$497K
(-43.39%↓ Y/Y)
Accrued expenses
$431K
(130.52%↑ Y/Y)
Prepaid expenses and
other current assets
-$371K
(61.03%↑ Y/Y)
Other receivables
-$54K
(-107.84%↓ Y/Y)
Loss on disposal of
fixed assets
-$14K
Net cash used in
operating activities
-$29,917K
(54.57%↑ Y/Y)
Canceled cashflow
$7,296K
Net loss
-$36,650K
(49.07%↑ Y/Y)
Operating lease liability
-$563K
(-4.65%↓ Y/Y)
Back
Back
Cash Flow
Inhibrx Biosciences, Inc. (INBX)
Inhibrx Biosciences, Inc. (INBX)
source: myfinsight.com